Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.

Trial Details

NCT ID
NCT06222593
Phase
PHASE1 / PHASE2
Sponsor
State University of New York at Buffalo
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Bicalutamide in combination with Sunitinib
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Be willing and able to provide written informed consent for the trial.
  • Be greater than or equal to 18 years of age on day of signing informed consent.
  • Have measurable disease based on RECIST 1.1
  • Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →